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Abstract
Backround—Reactive oxygen species (ROS) mediate the effects of anesthetic precondition to
protect against ischemia and reperfusion injury, but the mechanisms of ROS generation remain
unclear. In this study, we investigated if mitochondria-targeted antioxidant (mitotempol) abolishes
the cardioprotective effects of anesthetic preconditioning. Further, we investigated the mechanism
by which isoflurane alters ROS generation in isolated mitochondria and submitochondrial
particles.
Methods—Rats were pretreated with 0.9% saline, 3.0 mg/kg mitotempol in the absence or
presence of 30 min exposure to isoflurane. Myocardial infarction was induced by left anterior
descending artery occlusion for 30 min followed by reperfusion for 2h and infarct size
measurements. Mitochondrial ROS production was determined spectrofluorometrically. The effect
of isoflurane on enzymatic activity of mitochondrial respiratory complexes was also determined.
Results—Isoflurane reduced myocardial infarct size (40±9 % = mean±SD) compared to control
experiments (60±4 %). Mitotempol abolished the cardioprotective effects of anesthetic
preconditioning (60±9%). Isoflurane enhanced ROS generation in submitochondrial particles with
NADH, but not with succinate, as substrate. In intact mitochondria, isoflurane enhanced ROS
production in the presence of rotenone, antimycin A, or ubiquinone when pyruvate and malate
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were substrates, but isoflurane attenuated ROS production when succinate was substrate.
Mitochondrial respiratory experiments and electron transport chain complex assays revealed that
isoflurane inhibited only complex I activity.
Conclusions—The results demonstrated that isoflurane produces ROS at complex I and III of
the respiratory chain via the attenuation of complex I activity. The action on complex I decreases
unfavorable reverse electron flow and ROS release in myocardium during reperfusion.
Introduction
Volatile anesthetics such as isoflurane have cardioprotective effects when administered
before a period of myocardial ischemia and reperfusion and this phenomenon is referred to
as anesthetic preconditioning (APC).1,2 It is accepted that mitochondria play a crucial role in
the mechanism of APC.3-5 Volatile anesthetics increase signaling quantities of reactive
oxygen species (ROS) production that serve as a mandatory step during triggering of APC,
and scavengers of ROS block APC-induced cardioprotection.6-8 Mitochondrial K+ influx
through mitochondrial ATP-sensitive K+ channels9 and/or Ca2+-activated K+ channels,10
uncoupling,3,5 mild depolarization11 and inhibition of mitochondrial respiration12,13 have
been suggested as possible mechanisms responsible for mitochondrial ROS generation
during APC. On the other hand, a burst of ROS generation during reperfusion exacerbates
ischemic injury, and this may be ameliorated by APC or by application of anesthetic at the
onset of reperfusion (anesthetic postconditioning).7,14 Thus, volatile anesthetics have
apparent directionally opposite effect on mitochondrial ROS production when applied prior
to ischemia or after reperfusion. The major sites responsible for mitochondrial ROS
generation are complex I and complex III of the electron transport chain (ETC).15 Our
previous study has demonstrated that ROS could be generated at complex III during APC16
while direct inhibitory effect of volatile anesthetics on complex I has also been
elucidated.12,13 Thus, the detailed molecular mechanism and sites of ROS generation during
APC are controversial.
In the present study, we investigated if mitotempol, a mitochondria-targeted superoxide
dismutase mimetic, abolished APC. We hypothesized that inhibition of ETC complex I by
isoflurane accounts for an increase of signaling ROS both, at complex I and at complex III,
and for a decrease of detrimental ROS at the time of reperfusion through inhibition of
reverse electron flow.
Methods and Materials
All experimental procedures and protocols used in the present study were reviewed and
approved by the Animal Care and Use Committee of the Medical College of Wisconsin, and
all were conformed to the Guiding Principles in the Care and Use of Animals of the
American Physiologic Society and were in accordance with the Guide for the Care and Use
of Laboratory Animals.
Surgical procedure and Experimental protocol
Male Wistar rats (270-320g) were randomly assigned to pretreatment with 0.9% saline
(control) or super oxide dismuatase mimetics, tempol (30 mg/kg) or mitotempol (3.0 mg/
kg). Mitotempol was synthesized by Dr. Joy Joseph (Ph.D., Associate Professor of
Biophysics, Medical College of Wisconsin).
The surgical procedure was performed as previously described. 17 Briefly, after rats were
anesthetized, the trachea was intubated for artificial ventilation. A thoracotomy was
performed and a suture was placed around the left anterior descending artery for coronary
artery occlusion and reperfusion. Systemic hemodynamics were recorded continuously on a
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polygraph and digitized using a computer connected to an analog-to-digital converter. The
experimental design for in vivo experiments is shown in Figure 1. Baseline hemodynamics
and arterial blood gas tensions were recorded for 30 min. All rats underwent 30 min of left
anterior descending artery occlusion followed by 2 h of reperfusion, in the absence or
presence of 30 min exposure to 1 minimum alveolar concentration of isoflurane in six
separate experimental groups (n=8 per group). After reperfusion, myocardial infarct size was
measured as previously described.18 Infarct size was expressed as percentage of the left
ventricular area at risk.
Isolation of rat heart mitochondria
Mitochondria were isolated from rat heart by differential centrifugation as previously
described.3 Hearts were excised and washed in isolation buffer [200 mM mannitol, 50 mM
sucrose, 5 mM KH2PO4, 5 mM 3-(N-morpholino) propanesulfonic acid, 1 mM EGTA, 0.1%
bovine serum albumin (BSA), pH 7.3 at 25°C adjusted with 5 M KOH] and minced into
small pieces. The suspension was homogenized in the presence of 5 U/mL of protease (from
Bacillus licheniformis) by using a T 25 dispenser (IKA-Werke, Staufen, Germany). The
mitochondrial pellets were resuspended in isolation buffer at a concentration of 10-20 mg/
mL, stored on ice and used for experiments within 4 h. Protein concentration was
determined using a modified Lowry assay kit (Bio-Rad, Hercules, CA).
The ROS scavenging effects of mitotempol and tempol
In order to assess the effectiveness of mitotempol and tempol to scavenge ROS, superoxide
anion generation was measured using the chemiluminescent probe 2-methyl-6-(p-
methoxyphenyl)-3,7-dihydroimidazo[1,2-α]pyrazin-3-one (MCLA) in the presence of
mitotempol or tempol. 0.5mg mitochondria were added to 1 ml respiration buffer containing
5 μM 2-methyl-6-(p-methoxyphenyl)-3,7-dihydroimidazo[1,2-α]pyrazin-3-one (MCLA)
and 5 mM pyruvate and malate were added to initiate superoxide generation. Antimycin A
(10 μM) was used to maximize ROS production rate. Chemiluminescence was measured in
a Modulus luminometer (Turner Biosystems, Sunnyvale, CA) at room temperature.
Measurement of mitochondrial ROS production
Mitochondrial ROS production was measured spectrofluorometrically using the fluorescent
probe amplex red (12.5 μM) in the presence of 0.1 U/ml horseradish peroxidase at 30°C.
Amplex red reacts with H2O2 in the presence of peroxidase and produces the red-fluorescent
product resorufin. Resorufin fluorescence was measured using a spectrofluorometer (Photon
Technology International, Birmingham, NJ) with excitation and emission wavelengths set at
530 and 583 nm, respectively. Measurements were performed in respiration buffer (130 mM
KCl, 5 mM K2HPO4, 20 mM 3-(N-morpholino) propanesulfonic acid, 2.5 mM EGTA, 1
μM Na4P2O7, and 0.1% BSA, pH 7.4) containing mitochondria at a final concentration of
0.5 mg protein/ml. ROS generation was stimulated with complex I substrates pyruvate (5
mM) and malate (5 mM) or complex II substrate succinate (5 mM) in the presence and
absence of isoflurane (0.5 mM). Rotenone (1 μM) and antimycin A (1 μM) were used to
inhibit the activities of complex I and complex III, respectively. Decylubiquinone (50 μM)
was used to estimate whether an increase of the ubiquinone/ubiquinol ratio affects ROS
production.19
Measurement of ROS production in submitochondrial particles (SMPs)
Submitochondrial particles (SMPs) were prepared by sonicating mitochondria on ice (10
bursts of 10 s at 20 watt). The sonicated suspension was centrifuged at 10,000 g for 10 min
(4 °C) and the supernatant was then centrifuged for 1 h at 100,000 g (4°C). The pellet was
resuspended in mitochondrial isolation buffer, and protein content determined.
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Measurements were performed in respiration buffer containing SMPs at a final
concentration of 0.5 mg protein/ml. ROS generation was stimulated with complex I
substrate NADH (0.5 mM) or complex II substrate succinate (5 mM) in the presence and
absence of isoflurane. Super oxide dismutase (100 units/ml) treatment was required when
NADH was used as substrate to reduce the substrate-dependent background rate of the
assay.20
Measurement of mitochondrial oxygen consumption
Mitochondrial oxygen consumption was measured in the presence or absence of isoflurane
(0.5 mM) by using an oxygen electrode (Hansatech Instruments, Norfolk, United Kingdom)
maintained at 30°C and experiments were conducted in respiration buffer containing 0.5 mg/
ml of mitochondrial protein. State 2 respiration was initiated with complex I substrates
pyruvate (5 mM) and malate (5 mM) or complex II substrate succinate (5 mM) in the
presence and absence of complex I inhibitor rotenone (1 μM). State 3 respiration was
measured in the presence of 250 μM ADP, and state 4 was monitored after complete ADP
consumption.
Electron transport chain (ETC) assay
ETC enzyme activity was measured spectrophotometrically as specific donor-acceptor
oxidoreductase activity.21,22 Isolated mitochondria were solubilized with 2% cholic acid and
diluted to a final concentration of 100 μg/ml in the experimental buffer [220 mM D-
mannitol, 70 mM sucrose, 5 mM 3-(N-morpholino) propanesulfonic acid, 2 mM EDTA, and
0.2% BSA (pH 7.4)]. In the isoflurane-treated group, isoflurane (0.5 mM) dissolved in
DMSO was added just before the reaction.
Complex I (NADH-ubiquinone oxidoreductase) activity assay
Complex I activity was determined by the rotenone-sensitive reduction of NADH
absorbance using decylubiquinone as acceptor. The assay mixture contained 20 μg/mL
mitochondrial protein, 50 mM KH2PO4, 0.1 mM EDTA, 0.1% BSA, 0.15 mg/mL asolectin,
2 mM antimycin A, and 0.2 mM NADH in a spectrophotometer cuvette. The reaction was
initiated by adding 75 mM decylubiquinone, and the change in absorbance of NADH was
measured at 340 nm (ε = 6.22 mM-1cm-1).
Complex II (succinate-ubiquinone oxidoreductase) activity assay
The activity of complex II was determined by dichlorophenolindophenol reduction. The
assay mixture contained 20 μg/mL mitochondrial protein, 50 mM KH2PO4, 0.1 mM EDTA,
0.1% BSA, 5 mM NaN3, 0.5 mM duroquinone, and 25 mM dichlorophenolindophenol. The
reaction was initiated by adding 20 mM succinate, and the change in absorbance of
dichlorophenolindophenol was measured at 600 nm (ε = 21 mM-1cm-1).
Complex III (ubiquinol-cytochrome c reductase) activity assay
The activity of complex III was determined by antimycin A sensitive reduction of
cytochrome c in the presence of decylubiquinol. Decylubiquinol was synthesized according
to the method described by Trumpower.23 The assay mixture contained 5 μg/mL of
mitochondrial protein, 50 mM KH2PO4, 0.1 mM EDTA, 0.1% BSA, 3 mM NaN3, and 60
μM oxidized cytochrome c. The reaction was initiated by adding 100 μM decylubiquinol,
and the change in absorbance of cytochrome c was measured at 550 nm (ε = 18.5
mM-1cm-1).
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Complex IV (cytochrome c oxidase) activity assay
The activity of complex IV was assessed by the decrease in the rate of absorbance of
reduced cytochrome c at 550 nm (ε = 18.5 mM-1cm-1). The assay mixture contained 50 mM
KH2PO4, 0.15 mg/mL asolectin, and 40 μM reduced cytochrome c, and the reaction was
initiated by adding 1 μg/mL of mitochondrial protein.
Administration of isoflurane in vitro experiments
The appropriate volume of isoflurane stock solution dissolved in DMSO was added to the
experimental buffer to obtain the desired concentration (0.5 mM corresponding to
approximately 1 minimum alveolar concentration for rats). In control experiments, we
confirmed that our final DMSO concentration (below 0.2 % v/v) had no effect on
mitochondrial ROS production, oxygen consumption and electron transport chain assays. At
the end of each experiment, the isoflurane concentration was analyzed by gas
chromatography. The concentration of isoflurane varied by ±10% from the reported value.
Data analysis
All data are presented as mean± SD. Statistical analysis was performed with Origin 7
(OriginLab, Northampton, MA) software. Comparisons were performed using two-tailed
hypothesis testing. One-way analysis of variance was used for statistical analysis of
differences between groups, with Bonferroni's post hoc test. Student't t-test was used to test
for a difference between two groups. Heart rate, mean arterial pressure and rate-pressure
product were analyzed by one-way repeated measures analysis of variance. A P-value less
than 0.05 was considered statistically significant.
Results
Effects of MT on infarct size in vivo
There were no differences in baseline heart rate, mean arterial pressure and rate pressure
product between groups (Table 1). Mitotempol and tempol had no effect on hemodynamics.
Due to its cardiodepressant effects, heart rate, mean arterial pressure and rate pressure
product were briefly decreased by isoflurane, however, these values returned to baseline
before coronary artery occlusion. Isoflurane (Fig.2) significantly decreased infarct size
(40±9% of area at risk) compared to control experiments (60±4%). Mitotempol and tempol
alone had no effect on infarct size (58±7% and 59±5%, respectively) but abolished the
cardioprotection afforded by isoflurane (60±9% and 58±9%, respectively). The actions of
mitotempol and tempol to scavenge mitochondrial ROS were confirmed in isolated
mitochondria subjected to antimycin A. ROS production was significantly reduced in the
presence of mitotempol (3.7±1.3 relative light units/mg protein/sec) and tempol (3.4±1.2
relative light units/mg protein/sec) compared to the absence (59.5±6.4 relative light units/mg
protein/sec) of antioxidants.
ROS production in isolated mitochondria and submitochondrial particles
Isoflurane-dependent changes in resorufin fluorescence observed during state 2 respiration
in isolated mitochondria initiated by complex I-linked substrates pyruvate and malate or
complex II-linked substrate succinate are shown in Fig. 3A-D and 4A-C, respectively.
Rotenone, antimycin A and ubiquinone alone increased ROS generation when complex I-
linked substrates were used (Fig. 3A-C). While isoflurane alone did not alter ROS
production rate with complex I-linked substrates, it enhanced ROS generation in the
presence of rotenone (27.6±6.9 and 39.9±9.7 pmol H2O2/mg protein/min for the control and
isoflurane-treated groups, respectively), antimycin A (105.7±6.0 and 169.3±9.8 pmol H2O2/
mg protein/min) or ubiquinone (30.6±9.5 and 44.2±7.8 pmol H2O2/mg protein/min) (Fig.
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3D). However, when electrons were delivered to complex II by succinate, isoflurane alone
decreased ROS production rate (400.9±18.3 and 135±21.7 pmol H2O2/mg protein/min for
the control and isoflurane-treated groups, respectively), whereas isoflurane had no effect on
rotenone, antimycin A and ubiquinone-modulated ROS production (Fig. 4C).
When using SMP instead of intact mitochondria, ROS production rate significantly
increased in the presence of isoflurane alone with NADH as substrate (15.5±6.4 and
35.4±8.4 pmol H2O2/mg protein/min for the control and isoflurane-treated groups,
respectively), but not with succinate (6.1±1.1 and 6.4±1.0 pmol H2O2/mg protein/min) (Fig.
5A, B).
The effects of isoflurane on mitochondrial respiration
The effects of isoflurane on mitochondrial respiration initiated by pyruvate and malate or
succinate in the absence and presence of rotenone are shown in Fig. 6A-C. Isoflurane
significantly decreased state 3 respiration (72±11 nmol O2/min/mg protein) compared to the
control group (116±12 nmol O2/mg protein/min) when pyruvate and malate were used (Fig.
6D). When succinate was used in the absence of rotenone, isoflurane significantly increased
state 3 respiration (124±10 nmol O2/mg protein/min) compared to the control group
(109±13 nmol O2/mg protein/min) (Fig. 6E). On the other hand, isoflurane had no
significant effect on mitochondrial respiration when succinate was used in the presence of
rotenone. (Fig. 6F)
ETC complex activity assay in solubilized mitochondria
In order to further pinpoint the complexes targeted by isoflurane, the relative activities of the
ETC complexes were quantified in cholic acid-solubilized mitochondria (Fig. 7). Isoflurane
significantly reduced only complex I activity to 86±5% (356±18 nmol NADH/mg protein/
min) of control (410±30 nmol NADH/mg protein/min); no changes in the activities of other
complexes were observed (99±5, 97±3 and 97±5 % of control for Complex II, Complex III
and Complex IV activities, respectively).
Discussion
The present study showed that (1) mitochondrial-targeted antioxidant abolished the
cardioprotection of APC; (2) isoflurane enhanced ROS production in SMPs when complex
I-linked substrates were used, however, this occurred in intact mitochondria only in the
presence of rotenone, antimycin A or ubiquinone; (3) with a complex II-linked substrate,
isoflurane did not alter ROS production in SMPs, but decreased ROS production in intact
mitochondria; and (4) isoflurane directly attenuated complex I activity.
Low concentrations of ROS24,25 have been demonstrated to activate preconditioning
pathways. Volatile anesthetics such as sevoflurane26 and isoflurane6,16 have also been
shown to activate cardioprotective signaling through ROS-sensitive pathways. ROS
produced by volatile anesthetics activate a variety of proteins such as protein kinase C, Akt,
and glycogen synthase kinase-β, which ultimately causes a delay of permeability transition
pore opening, thereby protecting the myocardium against ischemia and reperfusion injury.27
Previous studies demonstrated that ROS scavengers abolished volatile anesthetic-induced
reduction in myocardial infarct size.6-8 Although mitochondria have been suggested as the
source of protective signaling ROS in APC,27 direct evidence for this was lacking.
Piperidine nitroxides such as tempol are well established antioxidants in vitro and in vivo.28
The antioxidant effect is based on their ability to catalyze the dismutation of superoxide and
to detoxify redox-reactive forms of transition metal ions. Mitotempol, accumulated in
mitochondria due to its cationic triphenylphosphonium moiety, is an effective antioxidant
due to its proximity to ETC-generated ROS.29 The current results demonstrate that
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scavenging of ROS with tempol and, more importantly, mitotempol abolishes isoflurane-
induced cardioprotection. While mitotempol is specific in mostly scavenging mitochondria-
originating ROS, tempol indifferently scavenges all sources of cellular ROS. This directly
implicates mitochondria as the source ROS responsible for protective signaling.
Complex I and Complex III are the major sites of ROS generation in mitochondria;15
however, the site responsible for volatile anesthetic-induced ROS generation remains
undefined. The following evidence supports the contention that complex I is a source of
isoflurane-induced ROS: Isoflurane increases ROS generation with complex I-, but not
complex II-linked substrates in SMPs (Fig. 5); and isoflurane only alters activity of complex
I, but not of the other complexes in solubilized mitochondria. However, isoflurane-induced
ROS generation in isolated mitochondria was not detected in our experiments when complex
I-linked substrates were used. This apparent discrepancy observed in isolated mitochondria
as compared with submitochondrial particles may have occurred because ROS generated at
complex I site are released into the mitochondrial matrix where they rapidly react with
manganese superoxide dismutase before interact with detection reagent in the buffer.15
Interestingly, in the presence of rotenone, antimycin A or ubiquinone, isoflurane enhanced
ROS production with complex I-linked substrates. In the case of complex I inhibitor
rotenone, the inhibitory effect of isoflurane on complex I is enhanced and thereby allows
isoflurane-induced H2O2 detection in the buffer. The contribution of antimycin A (inhibitor
of complex III) and ubiquinone (donates electrons to complex III in its reduced form) to
isoflurane-enhanced ROS generation suggests a possible involvement of complex III. It is
generally assumed that ROS at complex III is generated by oxygen reduction via electron
transfer from ubisemiquinone which is formed at the ubiquinol oxidation center. Inhibition
of electron flow downstream of this center, e.g. by antimycin A, increases ROS
generation.15 However, this mechanism is not able to explain isoflurane-enhanced ROS
generation at complex III because isoflurane did not affect electron flow at complex III as
demonstrated by the ETC complex assay. Recently, Dröse et al. have proposed an alternate
mechanism for ROS generation at complex III: They observed that ROS generation depends
on the redox state of the ubiquinone pool. An increased ubiquinone/ubiquinol ratio enhances
ROS generation at complex III.19 According to this mechanism, an electron is transferred to
oxygen from reduced downstream cytochrome bL to oxygen in a reverse reaction via
oxidized ubiquinone. We confirmed that exogenous ubiquinone enhanced ROS generation
with complex I substrates. Interestingly, isoflurane further enhanced ROS generation in the
presence of ubiquinone. Inhibition of complex I by isoflurane may further increase the
ubiquinone/ubiquinol ratio by decreasing the electron flow complex I to form reduced
ubiquinol, thereby enhancing ROS generation at the complex III site. Similarly, diazoxide,
independent of its putative effect on mitochondrial ATP-sensitive K+ channels, attenuates
ubiquinol level via inhibition of complex II, causing an increase in ROS at the ubiquinol
oxidation.30 Thus, inhibition of electron flow at upstream complexes could contribute to
ROS generation at complex III through changes in the ubiquinone/ubiquinol ratio. We
suggest a mechanism whereby isoflurane interacts with complex I and causes an increase in
ROS generation at the complex III site.
Ischemic or pharmacologic preconditioning-induced mitochondrial K+ influx through
mitochondrial ATP-sensitive K+ channels and/or Ca2+-activated K+ channels and
subsequent matrix alkalinization was previously suggested as underlying mechanism of
increased ROS production.31,32 For example, diazoxide, a putative mitochondrial ATP-
sensitive K+ channel agonist, produced pharmacological preconditioning by generating
small quantities of ROS.33 However, several studies have demonstrated K+-independent
action of diazoxide, specifically interaction with the ETC that might be also related to ROS
production as mentioned before.30,34,35 APC has been associated with mild mitochondrial
depolarization, possibly through mitochondrial K+ channel opening10,36 and mild
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mitochondrial uncoupling has been shown to be cardioprotective.3,37,38 While a parallel
increase in ROS production and depolarization during APC seems counterintuitive in view
of the general assumption that mitochondrial depolarization decreases ROS production,11 it
may be the result of multiple actions of isoflurane on mitochondrial bioenergetics. Future
studies will elucidate the interactive mechanism between volatile anesthetic-induced ROS
generation via ETC interaction and K+ flux- or otherwise induced mitochondrial
depolarization.
In agreement with our results from complex activity measurements, isoflurane inhibited
oxygen consumption in the presence of complex I-linked substrates, but not when succinate,
as complex-II linked substrate, was used in the presence of rotenone. When succinate was
used in the absence of rotenone, isoflurane in fact increased the oxygen consumption. This
again points to complex I as the target of isoflurane. Succinate is converted to fumarate and
malate and then to oxaloacetate in the Krebs cycle without rotenone.39 Oxaloacetate
participates in a direct feedback inhibition of complex II that results in decreased oxidation
of succinate. When complex I activity is inhibited, NADH oxidation and, thereby, the levels
of NAD+ are decreased, which in turn, impairs the oxidation of malate to oxaloacetate.40
Therefore, inhibitory effects of isoflurane on complex I could increase complex II-linked
respiration via attenuation of oxaloacetate generation.
While a limited increase in ROS generation is critical for initiating prosurvival signaling
pathways during APC, oxidative stress contributes to mitochondrial and cellular injury
during reperfusion. With succinate as substrate, electrons entering the ETC at complex II
can generate ROS by reverse electron flow to complex I. Rotenone that blocks complex I
largely attenuates reverse flow-induced ROS generation.41 Similarly, isoflurane significantly
reduces ROS generation induced by reverse electron flow when a complex II substrate is
used. This action may be particularly relevant during myocardial ischemia, since succinate
concentration significantly increases during hypoxia.42,43 Isoflurane applied at the onset of
reperfusion (anesthetic postconditioning) may attenuate reverse electron flow-induced ROS
generation, thereby delaying the opening of mitochondrial permeability transition pore and
increasing cell survival.14 Thus, the source and mechanism of ROS generation observed
during reperfusion is likely to be fundamentally different from that of “ triggering” ROS
elicited during APC.
The current results should be interpreted within the constraints of several limitations.
Experiments were conducted in an established model of myocardial infarction in rats; thus,
these results may not be directly comparable to those obtained in humans. We were unable
to measure the effect of tempol and mitotempol on the small amount of ROS generated by
isoflurane directly in vitro experiments. Tempol and mitotempol convert superoxide anion to
hydrogen peroxide similarly to superoxide dismutase. Therefore, the scavenging properties
of those superoxide dismutase mimetics cannot be detected with the very sensitive amplex
red-based assay that detects hydrogen peroxide. On the other hand the methyl-6-(p-
methoxyphenyl)-3,7-dihydroimidazo[1,2-α]pyrazin-3-one (MCLA)-based assay is not
sensitive enough for this purpose.44 Nevertheless, we are confident that tempol and
mitotempol would scavenge isoflurane-induced ROS as they attenuated the large amount of
ROS induced by antimycin A in our measurements. In addition, measurements of ROS
production and other mitochondrial parameters were performed in vitro as it is virtually
impossible to evaluate subcellular regulation of ROS generation in the intact heart. We also
did not assess the interplay between mitochondrial depolarization and ROS generation and
this is the aim of ongoing studies in the laboratory.
In summary, our results confirmed the critical role of isoflurane to modulate mitochondrial
ROS. The interaction of isoflurane with complex I of the ETC is responsible for generation
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of signaling ROS at complex I and, indirectly, at complex III. Isoflurane also attenuates
reverse electron flow-induced damaging ROS production that occurs during reperfusion.
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What we already know about this topic
• Anesthetic preconditioning and protection from myocardial ischemic injury
involves reactive oxygen species (ROS), but the mechanisms for this are
unknown
What this article tells us that is new
• In rats, isoflurane preconditioning reduced subsequent myocardial infarction
size by 40% and generated ROS primarily through inhibition of Complex I
activity in mitochondria
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Summary Statement
Interaction of isoflurane with complex I in mitochondria is responsible not only for
reactive oxygen species generation at complex I and III, but also mitigates harmful
reverse electron flow-induced reactive oxygen species production.
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Figure 1.
Experimental protocols used for the production of coronary artery occlusion (OCC) and
reperfusion in rats treated with saline vehicle (CON), tempol (TEM), mitotempol (MT), and
with and without 1.0 minimum alveolar concentration (MAC) isoflurane (ISO). n=8/group.
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Figure 2.
Myocardial infarct size expressed as a percentage of the left ventricular area at risk (AAR)
in rats pretreated with saline vehicle (Con), tempol (TEM) and mitotempol (MT), and in the
absence or presence of isoflurane (ISO). Data are presented as mean±standard deviation .
n=8/group. *P<0.05 versus Con.
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Figure 3.
Reactive oxygen species (ROS) production in isolated mitochondria with pyruvate and
malate (P/M) as substrates. Representative traces show that rotenone (A), antimycin-A (B),
and ubiquinone (C) induced ROS production to a larger extent in the presence compared
with the absence (Con) of isoflurane (Iso). (D) Summary of the recordings. Summary data
are mean±SD. P/M alone; n=10/group. Rotenone, antimycin-A and ubiquinone; n=8/group.
*P<0.05 versus corresponding Con, #P<0.05 versus respective Con with P/M alone.
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Figure 4.
Reactive oxygen species (ROS) production in isolated mitochondria with succinate (Succ) as
substrate. The effects of antimycin-A (A) and ubiquinone (B) on complex II-linked ROS
production in the presence or absence (Con) of isoflurane (Iso) were analyzed after reverse
electron flow induced-ROS was blocked by rotenone. Iso reduced reverse electron flow
induced-ROS production in the absence of rotenone, however, Iso had no effect in the
presence of rotenone, and antimycin A or ubiquinone. (C) Summary of recordings. Data are
presented as mean±SD, n=8/group, *P<0.05 versus corresponding Con, #P<0.05 versus the
respective Con with Succ alone, §P<0.05 versus respective Con with rotenone.
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Figure 5.
Reactive oxygen species (ROS) production in submitochondrial particles (SMP) with
complex I (NADH) and complex II (succinate) substrates in the presence or absence (Con)
of isoflurane (Iso). Representative traces (A) show the effects of Iso on ROS production
using the different substrates (S). Iso induced ROS generation only when NADH was used
as substrate, but had no effect when succinate (Succ) was used. (B) Summary data are mean
±SD, n=8/group, *P<0.05 versus Con.
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Figure 6.
Effect of isoflurane (Iso) on mitochondrial respiration using substrates pyruvate/malate (P/
M), succinate (Succ), and adenosine diphosphate (ADP) in the absence or presence of Iso.
Representative traces demonstrate the effect of Iso on oxygen consumption using P/M (A),
Succ (B) and Succ+rotenone (C). Iso decreased mitochondrial respiration compared to the
control group (Con) when P/M were used (D). When Succ was used in the absence of
rotenone, Iso significantly increased mitochondrial respiration (E). Iso had no significant
effect on mitochondrial respiration when Succ was used in the presence of rotenone (F).
Summary data are mean±SD. P/M; n=10/group. Succinate and Succinate+Rotenone; n=8/
group. *P<0.05 versus Con.
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Figure 7.
The effects of (Iso) on the activity of the electron transport chain complexes. Enzymatic
activity for each complex during Iso is expressed relative to the absence (Con) of Iso. Data
are mean±SD, n=8/group, *P<0.05 versus (Con).
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